Lactulose

Introduction Overview

Generic Name

lactulose

Brand Name

Constulose, Generlac, Kristalose, Chronulac, Cephulac, Constilac, Cholac, Duphalac, Evalose, Heptalac, Enulose

Dosage Form

oral powder for reconstitution, oral syrup, oral and rectal liquid

Drug Class

Laxatives

Pharmacokinetics

Absorption:
Lactulose is a synthetic disaccharide composed of galactose and fructose that is not absorbed or metabolized by the human small intestine. After oral administration, lactulose resists enzymatic digestion in the upper gastrointestinal tract and reaches the colon largely intact. There, it is metabolized by colonic bacteria to produce organic acids such as lactic acid, acetic acid, and formic acid. These metabolites lower colonic pH and increase osmotic pressure, resulting in water retention within the bowel and promoting laxative effects. Because lactulose is minimally absorbed systemically, plasma levels remain negligible, minimizing systemic exposure and toxicity.

Distribution:
Since lactulose is not absorbed in the gastrointestinal tract, it has minimal systemic distribution and does not reach significant plasma concentrations. Its distribution is primarily limited to the colon where it exerts its therapeutic effects. However, orally or rectally administered lactulose effectively alters the colonic environment by fostering growth of beneficial bacterial flora, which can have additional clinical benefits, such as reduction of circulating ammonia in hepatic encephalopathy via bacterial metabolism.

Metabolism:
The metabolism of lactulose occurs exclusively via bacterial fermentation within the colon. Colonic bacteria metabolize lactulose into short-chain fatty acids (mainly lactic acid and acetic acid). This bacterial metabolism is fundamental to lactulose’s pharmacological effects, as it leads to acidification of the colonic contents, osmotic water retention, and ultimately laxation. The production of acidic metabolites also converts ammonia (NH3) into ammonium ions (NH4+), which are less absorbable, thereby reducing ammonia levels in portal and systemic circulation which is critical in managing hepatic encephalopathy.

Elimination:
Because lactulose is minimally absorbed, the parent compound itself is eliminated primarily via feces. The metabolites generated by bacterial fermentation are largely retained in the intestinal lumen or absorbed and metabolized further by colonic mucosa and liver. The unabsorbed lactulose and its metabolites are excreted with feces, which facilitates the laxative effect by promoting stool softening and increased bowel movements. There is negligible renal elimination of lactulose since systemic absorption is minimal.

Dosage Forms

Available Dosage Forms:
Lactulose is available in multiple oral and rectal formulations:
- Oral powder for reconstitution: 10 grams and 20 grams packets
- Oral syrup: 10 grams per 15 mL
- Oral and rectal liquid: 10 grams per 15 mL

Dosages for Adults and Adolescents:
- For chronic constipation: 15 mL orally once daily, adjusted as needed to produce soft stools, generally within 24-48 hours.
- For acute constipation: initial dose 15 mL orally once daily, continued until normal bowel function returns.
- For hepatic encephalopathy: initial dose 30 mL orally three times daily or 300 mL diluted in 700 mL water or saline as an enema, retained for 30-60 minutes every 4-6 hours; maintenance dose is 30-45 mL orally three times daily.

Specific Patient Populations:
- Pediatric patients with hepatic encephalopathy:
- Infants: 1.7-6.7 g/day (2.5-10 mL) orally divided into 3-4 doses, titrated to achieve 2-3 soft stools per day.
- Children: 26.7-60 g/day (40-90 mL) orally divided in 3-4 doses, adjusted similarly.
- Pediatric chronic constipation: 0.7-2 g/kg/day (1-3 mL/kg/day) orally in divided doses, not exceeding adult maximum of 40 g/day (60 mL/day).

Clinical guidelines recommend titrating the dose to produce 2-3 soft stools daily, monitoring for potential side effects such as diarrhea or electrolyte disturbances. The choice of formulation and route (oral or rectal) depends on patient tolerance, severity of constipation or encephalopathy, and clinical context.

Mechanism Of Action

Lactulose exerts its therapeutic effects primarily through its unique biochemical and physiological actions in the gastrointestinal tract. As a synthetic disaccharide composed of galactose and fructose, it is not absorbed in the small intestine, allowing it to reach the colon largely unchanged. Once in the colon, intestinal bacteria metabolize lactulose to short-chain fatty acids including lactic acid, acetic acid, and formic acid. This bacterial fermentation significantly lowers the colonic pH, creating a mildly acidic environment.

The acidic milieu results in an osmotic gradient that draws water into the colon, increasing fecal water content and stimulating peristalsis. This osmotic laxative effect softens stools and facilitates bowel movements, making lactulose effective for treating constipation. Additionally, the acidification leads to conversion of ammonia (NH3), a neurotoxic metabolite elevated in liver failure, into ammonium ions (NH4+), which are less diffusible and thus trapped within the gut lumen. This process reduces systemic ammonia absorption and circulating ammonium levels, which is critical in the management and prevention of hepatic encephalopathy.

At the cellular level, lactulose indirectly modifies the composition of gut microbiota by promoting proliferation of beneficial acidophilic bacteria, thereby improving intestinal flora balance. This alteration may further enhance ammonia metabolism and reduce production of harmful gut-derived toxins. Compared to other laxatives, lactulose’s dual action of osmotic laxation and ammonia reduction provides a uniquely beneficial therapeutic profile, especially in patients with hepatic dysfunction.

Clinical studies have consistently demonstrated lactulose’s efficacy in improving bowel habits in chronic constipation and in decreasing elevated blood ammonia levels to ameliorate hepatic encephalopathy symptoms. The slow onset of 24-48 hours and the need for dose titration to avoid diarrhea reflect its gradual modulation of colonic environment. Research also indicates improvements in neurocognitive function and quality of life in patients using lactulose for hepatic encephalopathy, underscoring the clinical significance of its multifaceted mechanism of action.

Pharmacological Actions

Osmotic laxative function increasing water content in the colon to soften stools
Fermentation by colonic bacteria producing organic acids that acidify the bowel contents
Lowering colonic pH facilitating ammonia conversion and trapping in the gut lumen
Promotion of beneficial gut microbiota proliferation and balance
Reduction of systemic blood ammonia levels to treat hepatic encephalopathy
Facilitation of regular bowel movements in chronic and acute constipation
Minimal systemic absorption leading to localized gastrointestinal effects
Use as an enema for rapid colonic cleansing in hepatic encephalopathy
Modification of intestinal environment reducing bacterial toxin absorption
Non-systemic mechanism minimizing systemic side effects
Slow onset of action favoring gentle bowel stimulation over abrupt evacuation
Dose-dependent laxative and ammonia-reducing effects
Compatibility with long-term use and chronic conditions

Therapeutic Or Clinical Uses

Treatment of chronic constipation to facilitate regular bowel movements
Management of acute constipation episodes with gradual symptom relief
Prevention and treatment of hepatic encephalopathy associated with liver failure
Reduction of elevated blood ammonia levels to improve neurological function
Supportive therapy to improve intestinal flora in patients with hepatic disease
Use as a bowel cleansing agent prior to colonoscopy or diagnostic procedures
Adjunctive therapy in opioid-induced constipation
Pediatric use for chronic constipation and hepatic encephalopathy under dosing supervision
Alternative laxative for patients intolerant to stimulant laxatives
Management of constipation in elderly and debilitated patients
Treatment to reduce complications related to portal systemic shunting
Use in patients with encephalopathy to reduce confusion and cognitive decline
Therapeutic role in maintaining electrolyte balance through controlled dosing
Employment in cases requiring gentle and progressive colon cleansing
Off-label uses for gut microbiota modulation in metabolic and neuropsychiatric disorders (experimental)

Side Or Adverse Effects

Bloating and increased flatulence due to bacterial fermentation
Abdominal cramping and stomach discomfort secondary to colonic gas production
Diarrhea resulting from excessive osmotic water retention
Nausea and occasional vomiting in sensitive individuals or with higher doses
Electrolyte imbalances, specifically hypokalemia, during prolonged or excessive use
Dehydration risk from persistent watery stools
Allergic reactions such as hives, swelling, or respiratory difficulties (rare)
Potential for abdominal distension and discomfort during therapy initiation
Rare reports of intestinal obstruction in patients with pre-existing bowel abnormalities
Possible transient flatulence and minor intestinal noise during early treatment
May exacerbate symptoms of irritable bowel syndrome in some individuals
Overdose symptoms including severe diarrhea, electrolyte abnormalities, and systemic weakness
Tolerance development without dose adjustment may reduce efficacy
Rectal irritation if used as enema with improper administration
Minimal systemic adverse effects due to lack of absorption

Precautions

Use with caution in patients on a galactose-restricted diet as lactulose contains galactose
Monitor diabetic patients closely due to sugar content and potential impact on glycemic control
Avoid concomitant use with other laxatives or antacids unless recommended by a physician
Careful dose titration to prevent diarrhea and associated electrolyte disturbances
Consider frequent monitoring of electrolytes, especially potassium and sodium, during prolonged therapy
Patients undergoing colonoscopy should inform their doctors about lactulose use
Avoid use in cases of intestinal obstruction or acute surgical abdomen
Pregnant and breastfeeding women should use lactulose under medical supervision
Patients with history of hypersensitivity to lactulose or components should avoid use
Use caution in elderly or debilitated patients due to increased sensitivity to dehydration
Discontinue or adjust dosage in case of persistent diarrhea to prevent complications
Ensure adequate hydration to mitigate osmotic dehydration effects
Inform healthcare provider of all medications as drug interactions can affect efficacy
Be vigilant for signs of abdominal distension and severe cramping
Adjust dosing with respect to pediatric age and weight to avoid adverse events

Warnings

Do not exceed recommended dosage to avoid severe diarrhea and electrolyte imbalance
Immediate medical attention if signs of an allergic reaction occur, such as swelling or difficulty breathing
Stop use and consult a physician if severe or ongoing diarrhea develops
Avoid use in patients with undiagnosed abdominal pain or suspected bowel obstruction
Use cautiously in patients with diabetes mellitus due to sugar components
Potential for electrolyte abnormalities with prolonged or high-dose use
Not intended for rapid relief; onset may take 24 to 48 hours
Discontinue before diagnostic intestinal procedures as instructed by healthcare provider
Avoid freezing of the product to maintain efficacy
Discard product if liquid becomes very dark or changes consistency significantly
Ensure accurate dosing using supplied measuring devices to prevent overdose
Advise patients against abrupt cessation after long-term use to prevent rebound constipation
Monitor for neurological changes in hepatic encephalopathy patients to adjust dosing
Use only under medical supervision in hepatic encephalopathy cases
Warn patients about potential gastrointestinal discomfort during initial therapy phase

Contraindication

Hypersensitivity or allergy to lactulose or any component of the formulation
Patients on a strict galactose-restricted diet
Galactosemia or other disorders involving galactose metabolism
Presence of intestinal obstruction or acute surgical abdomen
Patients with sudden abdominal pain of unknown cause
Severe dehydration or electrolyte imbalance at baseline
Use contraindicated in patients with hypersensitivity reactions to disaccharides
Contraindicated if product integrity is compromised (e.g., very dark or altered consistency)
Should not be used without medical supervision in patients with undiagnosed severe constipation
Avoid use in patients with colonic ulceration or ischemic colitis
Situations where laxative use is not clinically appropriate such as appendicitis
Contraindicated for parenteral administration; only enteral routes are indicated
Patients with severely impaired digestive function without close monitoring
Use contraindicated in patients with known intestinal perforation
Not appropriate for immediate bowel evacuation in emergency situations requiring rapid clearance

Drug Interactions

Simultaneous use with antacids may reduce the efficacy of lactulose due to altered GI pH
Other laxatives may potentiate the osmotic effects leading to increased diarrhea and electrolyte loss
Concurrent use with diuretics may increase risk of hypokalemia when used long-term
Mineral oil may decrease lactulose absorption leading to reduced effectiveness
Medications that alter gastrointestinal motility may affect the onset and intensity of lactulose’s action
Certain antibiotics may modify colonic flora and thus influence lactulose metabolism and efficacy
Interference with drugs requiring precise intestinal pH for absorption (e.g., some azoles)
Coadministration with other drugs affecting electrolyte balance should be monitored carefully
Drugs that cause constipation (e.g., opioids) may require adjusted lactulose dosing
Potential interaction with oral contraceptives via altered gut flora though clinical significance is limited
Polyvalent cations and phosphate binders could modify lactulose effects by altering colonic environment
Herbal products with laxative properties may amplify lactulose-induced diarrhea
Vitamins and supplements that affect GI motility may influence lactulose tolerability
No significant systemic CYP enzyme interactions due to minimal absorption
Monitoring recommended when combining with drugs that affect CNS in hepatic encephalopathy patients

Preparations Of The Drug

Constulose: oral solution and syrup formulations for constipation and hepatic encephalopathy
Generlac: oral syrup and powder for reconstitution
Kristalose: sterile oral solution available for constipation and liver-related complications
Chronulac: oral syrup formulation prescribed for bowel regulation
Cephulac: oral liquid and powder formulations
Constilac: oral syrup used for laxative and hepatic encephalopathy indications
Cholac: oral liquid preparation
Duphalac: widely used oral syrup and powder with laxative indications
Evalose: oral syrup and solution for encephalopathy and constipation
Heptalac: solution often used in hepatic encephalopathy management
Enulose: oral liquid formulation specialized for hepatic encephalopathy and constipation
Available as powder packets, allowing reconstitution with water or fruit juice for ease of administration
Solutions and syrups provided with calibrated dosing devices for accuracy
Rectal liquid formulations used for enemas in hepatic encephalopathy
Shelf-stable formulations requiring storage at room temperature away from moisture and heat